Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II trial of PALI 2108

Next Previous
Trial Profile

A phase II trial of PALI 2108

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 29 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PALI 2108 (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use

Most Recent Events

  • 12 May 2026 According to a Palisade Bio media release, trial expected to commence in third quarter of 2026 and Data readout expected in second half of 2027.
  • 07 Jan 2026 According to a Palisade Bio media release, the Crohn's & Colitis Foundation, through its IBD Ventures program, approved a strategic equity investment of up to 500,000dollar and this will support the continued clinical and mechanistic development of PALI-2108, as the company looks to advance the program into the next stages of clinical development.
  • 03 Oct 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top